UK lab group LGC is being sold by Rothschild with several private equity houses and industrials in the frame. The interest shows that the food, environmental, clinical testing and diagostic lab spaces are starting to converge.
Four Seasons is the latest big British nursing home group to hit problems. It should make its December debt payment, but will run out of money by June/July 2016, say our sources. Guy Hands, the high profile boss of owner private equity investor Terra Firma, faces critiicism.
Wage hikes, old buildings and low tariffs spell disaster. But there could be a silver lining after 2020 – if anyone is left alive in the publicly paid for residential care sector.
Big pharma is trying and failing to engage with patients and has no idea how to build service models. Previous attempts to create websites that directly engage with consumers have flopped. The appallingly-named “patient-centricity” sessions at the FT Global Pharmaceutical and Biotechnology Conference suggest pharma is still trying in vain.
Shares in UK hospital chain Spire, where Mediclinic has a 30% stake, dived over 10% on warnings of a drop in private medical insurance business in the four months to October 2015. Spire also faces problems on the NHS side of its business with likely tariff cuts and a collapse in local contracts in the four months to October. Self-pay is also off. What are the ramifications for other players?
European countries are undergoing rapid and substantial demographic and technological changes. Yet, healthcare systems are still mainly state-funded and acute-focused, as they have been for the past 70 years. This is starting to change.
Measuring and delivering quality is going to be massively important for all private sector operators over the next five years - whether in acute care or elderly care. And initiatives are emerging which really should give transparency. Take the Private Healthcare Information Network in the UK.
We hear that Labcorp, the big US lab group is the latest potential bidder to kick the types at Unilabs, the Pan-West European lab group which Rothschild has put on the block. We analyse the bidders in an endgame of consolidation.
Healthcare Business International users cookies to improve the functionality, performance, and effectiveness of our communications. Detailed information on the use of cookies is provided in our Cookies Policy. By continuing to use this site, or by clicking "I agree" you consent to the use of cookies.